Bidness ETC |
Amgen and Sanofi to Cut Cholesterol Molecules' Prices
Bidness ETC On Tuesday,the Journal of the American Medical Association in a study opined that Amgen, Inc. (NASDAQ:AMGN), Sanofi SA, and Regeneron's cholesterol-lowering molecules have to cut prices to more than two-third in order get momentum in the revenue ... Study Finds PCSK9s Are Not Cost-Effective, and Drugmakers Aren't Happy Cost-effectiveness of PCSK9 inhibitors for heterozygous FH or ASCVD PCSK9 inhibitors are not cost-effective, concludes JAMA article |
Amgen and Sanofi to Cut Cholesterol Molecules' Prices - Bidness ETC
Read More
0 Response to "Amgen and Sanofi to Cut Cholesterol Molecules' Prices - Bidness ETC"
Post a Comment